Haemonetics

NYSE HAE
$54.38 0.30 0.55%
Today share price
USA
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 43.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
3.14B
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
4.06B
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.32
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
49.48M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-30.35 %

Upcoming events Haemonetics

All events
No upcoming events scheduled

Stock chart Haemonetics

Stock analysis Haemonetics

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
18.75 34.98
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
4.18 2.91
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
11.38 18.61
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
2.57 2.01
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
17.62 7.40

Price change Haemonetics per year

52.23$ 93.38$
Min Max

Summary analysis Haemonetics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Haemonetics

Revenue and net income Haemonetics

All parameters

About company Haemonetics

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Address:
125 Summer Street, Boston, MA, United States, 02110
Company name: Haemonetics
Issuer ticker: HAE
ISIN: US4050241003
Country: USA
Exchange: NYSE
Currency: $
IPO date: 1991-05-09
Sector: Healthcare
Site: https://www.haemonetics.com